| Project/Area Number |
23659936
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | Chiba University |
|---|
Principal Investigator |
SHIIBA Masashi 千葉大学, 大学院・医学研究院, 准教授 (20301096)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
神津 由直 千葉大学, 医学(系)研究科(研究院), 助教 (70400942)
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | アルドースケトース還元酵素 / 口腔癌 / マイクロアレイ解析 / 抗癌剤多剤耐性遺伝子 / アルドケトース還元酵素(AKR) / 抗癌剤耐性 / メフェナム酸 / アルドース‐ケトース還元酵素（AKR） |
|---|
| Research Abstract |
Using microarray analysis, AKR1C family were up-regulated in all CDDP-resistant cell lines compared with CDDP-sensitive cell lines. We treated the chemoresistant cells with AKR1C siRNA or specific AKR1C inhibitor, mefenamic acid. In vivo, the antitumor growth effect of the combination therapy of mefenamic acid and CDDP/5-FU was greater than that with either mefenamic acid alone or CDDP/5-FU alone. In conclusion, combination CDDP and5-FU chemotherapy with mefenamic acid might be a great therapeutic system for chemoresistant OSCC. Toxicity of combination therapy of CDDP/5-FU and mefenamic acid was evaluated in vitro and in vivo, resulting in the recognition of the safety for the clinical application.
|
